South Korea
· Delayed Price · Currency is KRW Yuyu Pharma Statistics
Total Valuation
Yuyu Pharma has a market cap or net worth of KRW 75.73 billion. The enterprise value is 77.11 billion.
| Market Cap | 75.73B |
| Enterprise Value | 77.11B |
Important Dates
The last earnings date was Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Yuyu Pharma has 16.18 million shares outstanding. The number of shares has increased by 4.42% in one year.
| Current Share Class | 16.18M |
| Shares Outstanding | 16.18M |
| Shares Change (YoY) | +4.42% |
| Shares Change (QoQ) | +3.38% |
| Owned by Insiders (%) | 34.99% |
| Owned by Institutions (%) | 0.09% |
| Float | 10.52M |
Valuation Ratios
The trailing PE ratio is 15.30.
| PE Ratio | 15.30 |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | 3.65 |
| P/OCF Ratio | 2.92 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.38, with an EV/FCF ratio of 3.72.
| EV / Earnings | 15.45 |
| EV / Sales | 0.58 |
| EV / EBITDA | 4.38 |
| EV / EBIT | 6.45 |
| EV / FCF | 3.72 |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.60 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 1.64 |
| Interest Coverage | 3.91 |
Financial Efficiency
Return on equity (ROE) is 5.89% and return on invested capital (ROIC) is 4.45%.
| Return on Equity (ROE) | 5.89% |
| Return on Assets (ROA) | 3.64% |
| Return on Invested Capital (ROIC) | 4.45% |
| Return on Capital Employed (ROCE) | 8.21% |
| Revenue Per Employee | 502.46M |
| Profits Per Employee | 18.91M |
| Employee Count | 264 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.40% in the last 52 weeks. The beta is 0.46, so Yuyu Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -6.40% |
| 50-Day Moving Average | 4,532.30 |
| 200-Day Moving Average | 4,569.00 |
| Relative Strength Index (RSI) | 56.10 |
| Average Volume (20 Days) | 65,488 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Yuyu Pharma had revenue of KRW 132.65 billion and earned 4.99 billion in profits. Earnings per share was 305.85.
| Revenue | 132.65B |
| Gross Profit | 50.98B |
| Operating Income | 11.83B |
| Pretax Income | 7.80B |
| Net Income | 4.99B |
| EBITDA | 17.47B |
| EBIT | 11.83B |
| Earnings Per Share (EPS) | 305.85 |
Balance Sheet
The company has 45.55 billion in cash and 34.08 billion in debt, giving a net cash position of 11.46 billion or 708.27 per share.
| Cash & Cash Equivalents | 45.55B |
| Total Debt | 34.08B |
| Net Cash | 11.46B |
| Net Cash Per Share | 708.27 |
| Equity (Book Value) | 136.10B |
| Book Value Per Share | 7,617.36 |
| Working Capital | 39.20B |
Cash Flow
In the last 12 months, operating cash flow was 25.97 billion and capital expenditures -5.21 billion, giving a free cash flow of 20.75 billion.
| Operating Cash Flow | 25.97B |
| Capital Expenditures | -5.21B |
| Free Cash Flow | 20.75B |
| FCF Per Share | 1,282.51 |
Margins
Gross margin is 38.43%, with operating and profit margins of 8.92% and 4.63%.
| Gross Margin | 38.43% |
| Operating Margin | 8.92% |
| Pretax Margin | 5.88% |
| Profit Margin | 4.63% |
| EBITDA Margin | 13.17% |
| EBIT Margin | 8.92% |
| FCF Margin | 15.65% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 2.14%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 2.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.42% |
| Shareholder Yield | -2.30% |
| Earnings Yield | 6.59% |
| FCF Yield | 27.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 30, 2021. It was a forward split with a ratio of 2.
| Last Split Date | Mar 30, 2021 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Yuyu Pharma has an Altman Z-Score of 1.84. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | n/a |